Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(10), 3040-3100; doi:10.3390/ph3103040
Review

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants

1,2,* , 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2 and 1,2
Received: 28 May 2010; in revised form: 7 September 2010 / Accepted: 25 September 2010 / Published: 29 September 2010
(This article belongs to the Special Issue Alzheimer's Disease Drugs)
View Full-Text   |   Download PDF [524 KB, uploaded 29 September 2010]
Abstract: About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between variations in specific candidate genes and the positive and adverse effects of drug treatment. Approximately, 18% of neuroleptics are substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4. 10-20% of Western populations are defective in genes of the CYP superfamily; and the pharmacogenomic response of psychotropic drugs also depends on genetic variants associated with dementia. Prospective studies with anti-dementia drugs or with multifactorial strategies have revealed that the therapeutic response to conventional drugs in Alzheimer’s disease is genotype-specific. The disease-modifying effects (cognitive performance, biomarker modification) of therapeutic intervention are APOE-dependent, with APOE-4 carriers acting as the worst responders (APOE-3/3 > APOE-3/4 > APOE-4/4). APOE-CYP2D6 interactions also influence the therapeutic outcome in patients with dementia.
Keywords: Alzheimer’s disease; APOE; CYPs; genetics; pharmacogenomics Alzheimer’s disease; APOE; CYPs; genetics; pharmacogenomics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Cacabelos, R.; Fernández-Novoa, L.; Martínez-Bouza, R.; McKay, A.; Carril, J.C.; Lombardi, V.; Corzo, L.; Carrera, I.; Tellado, I.; Nebril, L.; Alcaraz, M.; Rodríguez, S.; Casas, Á.; Couceiro, V.; Álvarez, A. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals 2010, 3, 3040-3100.

AMA Style

Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, Corzo L, Carrera I, Tellado I, Nebril L, Alcaraz M, Rodríguez S, Casas Á, Couceiro V, Álvarez A. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals. 2010; 3(10):3040-3100.

Chicago/Turabian Style

Cacabelos, Ramón; Fernández-Novoa, Lucía; Martínez-Bouza, Rocío; McKay, Adam; Carril, Juan C.; Lombardi, Valter; Corzo, Lola; Carrera, Iván; Tellado, Iván; Nebril, Laura; Alcaraz, Margarita; Rodríguez, Susana; Casas, Ángela; Couceiro, Verónica; Álvarez, Antón. 2010. "Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants." Pharmaceuticals 3, no. 10: 3040-3100.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert